APLP2 gene The apl-2 peptide sequence refers to a specific arrangement of amino acids that defines the structure and function of a molecule known as APL-2. This molecule has garnered significant attention in biomedical research, particularly for its role as a PEGylated cyclic peptide inhibitor of complement C3APLP2 amyloid beta precursor like protein 2 [ (human)]. Understanding the precise amino acid sequence of APL-2 is crucial for its development as a therapeutic agent, especially for conditions involving the complement cascade.
The primary focus of APL-2, in its pegcetacoplan form, is its ability to inhibit complement protein C3作者：N Lorenzo·2024·被引用次数：38—This approach represents an attractive alternative for treatment of autoimmune diseases.APL-1 is an alteredpeptideligand derived from a novel CD4+ T-cell.. This inhibition is achieved through a specific peptide sequence that binds to C3, thereby disrupting the complement cascade215014Orig1s000 - accessdata.fda.gov. This cascade is a critical part of the immune system, but its dysregulation can lead to various autoimmune and inflammatory diseases.作者：EE Cutts·2020·被引用次数：6—Aplbinding at operator site O1 and O2was assumed to compete with RNAP binding at pR, since the conservedsequenceslies at pR –1 to –6, and +5 to +10, ... By targeting C3, APL-2 offers a potential treatment for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA), where uncontrolled complement activation causes significant harm.2020年8月10日—Thepeptideportion of the drug binds to complement C3 and is a broad inhibitor of the complement cascade, a biological process that is part of ...
APL-2 is characterized as a 15-amino acid cyclic peptideAPL2 - APL4 Interaction Summary. The cyclic nature means the peptide chain forms a ring, which can confer increased stability and resistance to degradation compared to linear peptides. Furthermore, APL-2 is often PEGylated, a process where polyethylene glycol (PEG) molecules are attached to the peptide2019年12月11日—Pegcetacoplan (APL-2) is aPEGylated cyclic peptide inhibitor of complement C3. PEGylation helps keep APL-2 in the body longer, reducing dosing .... This modification enhances its pharmacokinetic properties, such as increasing its half-life in the body and reducing the frequency of administration required for effective treatment. The sequence of these 15 amino acids, along with the PEGylation, dictates its binding affinity and inhibitory potency against C3.moiety and a 2-amino acidlinker) covalently coupled to each end of a linear 40 kDa PEG chain, so there are twopeptidemoieties per molecule ofAPL-2. The ...
The development of APL-2, particularly as pegcetacoplan, has been driven by the need for targeted therapies against complement-mediated diseases. Clinical trials have explored its efficacy in conditions like PNH, where it has shown promise in reducing hemolysis and improving patient outcomes. The detailed understanding of the apl-2 peptide sequence is fundamental for ongoing research and developmentSequence ID No. 2 presents thededuced amino acid sequencefor the nucleotide sequence set forth in Sequence ID No. 1. Sequence ID No. 3 presents the .... This includes efforts to:
* Optimize the peptide sequence: Researchers may explore variations in the amino acid sequence to enhance binding to C3, improve stability, or reduce potential off-target effects.
* Develop novel delivery methods: Knowledge of the peptide's properties aids in designing advanced drug delivery systems.2025年8月6日—Due to the key position of C3 in the complement cascade,APL-2, a cyclic peptide inhibitor of C3, may prevent both intravascular and ...
* Investigate new therapeutic targets: The insights gained from studying APL-2's interaction with C3 could lead to the identification of new therapeutic applications for complement inhibitors.
While pegcetacoplan is a prominent example, the term "APL-2" can also appear in other research contexts. For instance, "APL-2" has been described as an "altered peptide ligand derived from heat-shock protein 60," suggesting different molecular entities that share the APL designationN-terminus - Wikipedia. Additionally, there are references to "APL2" as a component of the AP-1 adaptor complex, involved in intracellular transport, and "APLP2" (Amyloid-like protein 2), a protein family member involved in hemostasis regulationmoiety and a 2-amino acidlinker) covalently coupled to each end of a linear 40 kDa PEG chain, so there are twopeptidemoieties per molecule ofAPL-2. The .... These distinct uses highlight the importance of context when encountering the "APL-2" nomenclature, though the most prominent and therapeutically relevant APL-2 refers to the complement inhibitor.2025年8月6日—Due to the key position of C3 in the complement cascade,APL-2, a cyclic peptide inhibitor of C3, may prevent both intravascular and ...
In conclusion, the apl-2 peptide sequence is the foundational element of a significant therapeutic agent, pegcetacoplanThis protein plays a role in synthesis of starch. It catalyzes the synthesis of the activated glycosyl donor, ADP-glucose from Glc-1-P and ATP.. Its precise arrangement of amino acids, coupled with PEGylation, enables potent inhibition of complement C3, offering new hope for patients suffering from debilitating complement-mediated diseases. Continued research into its sequence and mechanism of action promises further advancements in this critical area of medicine.作者：N Lorenzo·2024·被引用次数：38—This approach represents an attractive alternative for treatment of autoimmune diseases.APL-1 is an alteredpeptideligand derived from a novel CD4+ T-cell.
Join the newsletter to receive news, updates, new products and freebies in your inbox.